Kitaadachi-gun, Japan Clinical Trials

A listing of Kitaadachi-gun, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

mk-3475
leucovorin
chemoradiotherapy
pembrolizumab
esophageal carcinoma
Saitama Cancer Center ( Site 0564)
 (0.7 away) Contact site
  • 32 views
  • 26 Sep, 2021
  • +152 other locations
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered intravenously at 2.5 milligram (mg)/kilogram …

refractory multiple myeloma
ejection fraction
dexamethasone
neutrophil count
pomalidomide
GSK Investigational Site
 (7.4 away) Contact site
  • 5 views
  • 29 Apr, 2021
  • +103 other locations
Mid-Q Response Study

The Mid-Q Response study is a prospective, multi-center, randomized controlled, interventional, single-blinded, post-market study. The purpose of the Mid-Q Response study is to test the hypothesis that the AdaptivCRT (aCRT) algorithm is superior to standard CRT therapy regarding patient outcomes in CRT indicated patients with moderate QRS duration, preserved atrioventricular …

beta blockers
ejection fraction
angiotensin ii receptor antagonists
medical therapy
beta-adrenergic blocking agents
Saitama Medical Center Jichi Medical University
 (9.6 away) Contact site
  • 0 views
  • 23 May, 2021
  • +43 other locations
A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival

The main objective of this study is to evaluate safety and efficacy of venetoclax in combination with azacitidine (AZA) and best supportive care (BSC) compared to BSC as maintenance therapy in adult participants with acute myeloid leukemia (AML) in first remission after conventional chemotherapy. This study will be conducted in …

consolidation chemotherapies
remission
azacitidine
venetoclax
cancer
Saitama Med Ctr Jichi Med Univ /ID# 219148
 (6.5 away) Contact site
  • 40 views
  • 15 Sep, 2021
  • +306 other locations
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

lower respiratory tract infection
vaccination
prenatal
Saitama City Hospital
 (8.1 away) Contact site
  • 139 views
  • 26 Sep, 2021
  • +463 other locations
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

crohn's disease
colitis
ustekinumab
endoscopy
fistulising crohn's disease
Saitama Medical Center
 (8.6 away) Contact site
  • 794 views
  • 07 Sep, 2021
  • +806 other locations
A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to …

remission
Tokito Clinic /ID# 164253
 (9.9 away) Contact site
  • 630 views
  • 26 Sep, 2021
  • +926 other locations
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

mirikizumab
Tokitokai Tokito Clinic
 (9.9 away) Contact site
  • 257 views
  • 26 Sep, 2021
  • +620 other locations
Active Surveillance Bleomycin Carboplatin Etoposide or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as …

neutrophil count
tumor markers
cancer
seminoma
immature teratoma
Saitama Children's Medical Center
 (7.5 away) Contact site
  • 341 views
  • 08 Sep, 2021
  • +370 other locations
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the efficacy of ustekinumab dosing in inducing clinical remission (Global) and in maintaining clinical remission (US); to evaluate the safety profile and ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with moderately to severely active Crohn's disease.

faecal calprotectin
crohn's disease
colitis
pediatric onset crohn's disease
ustekinumab
Saitama Children's Medical Center
 (7.5 away) Contact site
  • 0 views
  • 08 Sep, 2021
  • +56 other locations